Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Frontera London

- PMLiVE

Amgen and UCB’s Evenity recommended by NICE for severe osteoporosis

In the UK, almost four million people are affected by osteoporosis, resulting in around 520,000 fragility fractures each year

- PMLiVE

ICR scientists create AI test to predict cancer drug combinations

The technique uses artificial intelligence (AI) to analyse large-scale protein data from tumour samples

- PMLiVE

The evolution of medical affairs – active cooperation, collaboration and communication

By Caron Kennedy

- PMLiVE

Expanding clinical trial access: a global imperative requiring local focus

By Pankaj Patel

- PMLiVE

Health technology assessments: understanding the global landscape and considerations for drug development

By Manpreet Sidhu (pictured) and Ben Cieply

- PMLiVE

DE&I: breaking out of the echo chamber

By Sam Bremner

- PMLiVE

Wilmington Healthcare appoints new director to lead cloud-based healthcare customer intelligence tool

Paul Rowe to lead intelligence tool that allows Industry to gain the complete picture of their changing NHS customer base and employ precision planning to access target customers and markets.

Wilmington Healthcare

Top 10 Tips for Creating Company Culture in a Virtual World

For many companies, the transition from in-office to remote or flexible work at the beginning of the pandemic may have started off a bit rocky. However, a recent survey from LinkedIn...

Impetus Digital

Democratizing Brain Health with Digital Assessments

Dr. Pam Ventola, Senior Science Director at Cogstate, shares how the company is working to optimize brain health assessments in rare disease and pediatric clinical trials, and how this can...

Impetus Digital

- PMLiVE

Innovative Trials suspends services in Russia in response to Ukraine war

Kate Shaw, Founder & CEO of the leading patient recruitment organisation based in Letchworth (UK), on the current Russia-Ukraine situation.

Innovative Trials

- PMLiVE

FDA grants Pfizer/BioNTech expanded EUA for an additional COVID-19 vaccine booster

The second booster authorisation is for those aged 50 years and older to promote high levels of protection against COVID-19 in the most vulnerable groups

- PMLiVE

Sanofi and IGM Biosciences agree on deal potentially worth over $6bn

The deal focuses on research into oncology, immunology and inflammation targets

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links